Introduction

Significance of myostatin
Myostatin (Mstn) is an important regulator of skeletal muscle growth. Mstn is a member of the TGF-β (transforming growth factor β) superfamily, mainly expressed in skeletal muscle, with less, but still significant expression in the heart and adipose tissues. Enhanced production of Mstn inhibits skeletal muscle growth and decreases muscle mass (e.g. in cachexia, muscle dystrophy or aging) while Mstn mutations cause hypermuscular phenotype in several different species.
Furthermore, Mstn plays a crucial role in the regulation of cardiomyocyte growth as well as in the maintenance of oxidative metabolism and contractility of the heart. In heart failure patients myocardium produces and secretes Mstn protein into the circulation thereby inhibiting skeletal muscle growth leading to cachexia. Mstn secreted by skeletal muscles might also have an impact on the heart and adipose tissues. Its mechanism of action has not been clarified in its full complexity so far, although it might be a promising therapeutical target molecule in both metabolic and muscle diseases.
Mstn is synthetized as a precursor protein in muscle cells and after cleaveage and secretion, forms an inactive complex with its propeptide. Once activated by propeptide proteases, the active Mstn binds to activin type IIB receptor (ActRIIB), which dimerizes with and phosphorylates type I receptor (ActRI). Mstn acts through different intracellular pathways with Smads representing the classical way to transduce Mstn effects by inhibiting protein synthesis, myoblast proliferation and differentitation and by activating protein degradation. 
Skeletal muscle development and adult muscle phenotype
Mstn was shown to play an important role in regulating skeletal muscle growth (hyperplasia: increase in cell number, hypertrophy: increase in cell size) and adult muscle phenotype. According to the ATPase activity of myosin heavy chains (MHC), slow type MHC I and fast type MHC II are distinguished giving rise to type I and type II fibers, respectively. Within type II fibers, oxidative MHCIIA, oxidative-glycolytic MHCIIX and glycolytic MHCIIB isoforms are identified, representing the dominating isoforms in type IIA, IIX and IIB fibers, respectively. Regulation of fiber types is only partly understood, but Mstn might be one of the candidates which may modulate oxidative versus glycolytic fiber type determination.
Myostatin mutations in skeletal muscle
The Mstn knock out (KO) mouse shows a hypermuscular phenotype similar to that of several different organisms (Piedmontese and Belgian Blue cattles, dog, pig, Texel sheep and human infant) carrying naturally occuring mutations in the biologically active part of Mstn. In contrast to aforementioned mutations, the hypermuscular Compact (Cmpt) mice which was originated from the Technical University of Berlin carry a 12-bp natural mutation in the Mstn propeptide, with additional modifier genes being responsible for the phenotype, however these genes have not been identified yet. To date, only few studies provided phenotypical or molecular analysis of the Cmpt mice although this line represents a complex and mainly unknown mechanism of Mstn-dependent hypermuscularity.
Role of cardiac myostatin, interplay between myostatin and IGF-I in the heart
Mstn has been identified as a key modulator of heart function by regulating growth, metabolism and contractility but its interaction with IGF-I has not been clarified in its full complexity. IGF-I was shown to play a pivotal role in cardiovascular physiology and aging. In concert with insulin itself, IGF-I proved to be a positive regulator of cardiac growth and contractility under both physiological and pathological conditions. Mstn might be a cardiac chalone of IGF-I, since cardiac growth induced by IGF-I was feed-backed by the overexpression of the negative growth regulator Mstn. According to the hypothesis, chalones are secreted by specific tissues and provide a negative feedback mechanism to control the size of tissue that produces it.
MicroRNAs (miRs) are small noncoding RNAs that negatively regulate cardiac gene expression under both physiological and pathological conditions with a potential impact on cardiac Mstn or IGF-I expression as well. Indeed, microRNA(miR)-208, has been reported to be a negative regulator of Mstn expression and to play a crucial role in pathological cardiac hypertrophy and fibrosis.
No studies have systematically analyzed the relevance of the possible reciprocal regulation of Mstn and IGF-I at the gene expression level in healthy or failing human hearts, nor the potential role of miR-208 under these conditions. Previous investigations focused only on Mstn protein activation in hearts of dilated or ischemic cardiomyopathic patients (DCM or ICM, respectively). Moreover, no data exist in the literature about the expression pattern of Mstn in comparison with IGF-I and their receptors in various regions (i. e. left (LV) and right ventricles (RV)) of the human heart. Given the different functional requirements LV and RV should cope with, and the markedly different development of these regions, one could assume that the gene expression pattern of Mstn and IGF-I signaling might show remarkable spatial differences under both physiological and pathological conditions. Aims 1. To describe the muscle phenotype of the Mstn mutant Cmpt mice using morphological assessments in order to uncover the combined effects of the unconventional propeptide 
Materials and Methods
Mouse studies: Animals and experimental design
Male, 2.5-month-old male Cmpt (44-50,7 g) and BALB/c (24-28g) mice were used for the experiments (n=5-10). Typical hindlimb muscles (m. quadriceps (Quadr), m. tibialis anterior (TA), m. extensor digitorum longus (EDL) m. soleus (SOL) and m. gastrocnemius (Gastro)) of Cmpt and BALB/c strains were removed under intraperitoneal anaesthesia. For comparison of body and muscle weights as well as for TA muscle fiber analysis, older Cmpt male mice were also used. All muscles were weighed and frozen in isopenthane/liquid nitrogen and kept at -80°C until further use. TA, EDL and SOL muscles of BALB/c and hypermuscular Cmpt mice from the right leg were used for morphological and immunohistochemical analysis while RNA isolation followed by qRT-PCR was carried out from the contralateral TA counterparts. Animal experiments were approved by the 
Human studies: Patients and experimental design
Healthy human hearts were obtained from organ donor patients (CONT, n=5) whose hearts were explanted but due to technical reasons not used for transplantation. The donors did not present any important previous medical history or any abnormalities in ECG and echocardiography and had died from head trauma, cerebral or subarachnoid hemorrhage. Explanted end-stage failing hearts were obtained from patients with advanced heart failure of non-ischaemic (DCM) (n=5) or ischaemic 
Morphological and morphometrical analysis of mouse skeletal muscles
10 µm serial cryostat sections were taken from the midbelly region of different muscles of both Cmpt and BALB/c mice followed by standard hematoxylin-eosin (HE) staining. By taking pictures from all microscopic fields the whole cross-sectional area (CSA) of each muscle was reconstructed and determined by counting all fibers in TA, EDL and SOL muscles with Digimizer software.
Myosin heavy chain (MHC) immunohistochemistry of mouse skeletal muscles
Sections were incubated with mouse monoclonal primary antibodies BA-D5 (1:25), sc-71
(1:25) and BF-F3 (1:5) specific for myosin heavy chain (MHC) I (slow oxidative), MHCIIA (fast oxidative) and MHCIIB (fast glycolytic), respectively. After incubation with the peroxidaseconjugated secondary antibody immunocomplexes were visualized by diaminobenzidine (DAB) staining with or without nickel enhancement. IIX fibers were considered as those not stained by any of the above antibodies. The size and distribution of muscle fibers were determined by analyzing at least 20-50% of fibers in SOL, EDL and TA muscles.
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Quantitative RT-PCR analysis of mRNA transcripts in mouse skeletal muscles and human heart samples Total RNA was isolated from TA muscles of Cmpt and BALB/c male mice (n=5) with TRI reagent or from the LV, S and RV samples of the CONT, DCM or ICM patients (n=5) with the acid guanidinium thiocyanate-phenol-chloroform (AGPC) method, followed by reverse transcription. For the detection of transcript levels of mouse MHCI, MHCIIA, MHCIIX and MHCIIB as well as human Mstn, ActRIIB, IGF-I, and IGF-IR quantitative RT-PCR was carried out with SYBR GREEN master mix on a Light Cycler 1.5. As an internal control, hipoxanthine-guanine phosphorybosyltransferase (hprt/HPRT) has been used in our experiments. Cycle conditions were set as an initial denaturation step, followed by 45 cycles for template denaturation, annealing and extension phases. Specificity of the PCR products was confirmed by melting curve analysis and by agarose gel electrophoresis (1.5%). Primer pairs were designed to intron spanning exons by Primer 3
Input software and tested to avoid primer dimers, unspecific amplification and self-priming formation.
Quantitative RT-PCR analysis of miRNA transcripts in human heart samples
From the above detailed total RNA isolates of human heart samples, cDNA was synthetized and quantitative real-time PCR was performed with miRCURY LNA TM Universal RT microRNA PCR kit (Exiqon, Denmark) on LightCycler®480 according to the manufacturer's instructions. The primers for both microRNA-208b and control microRNA-103a-3p were designed and prepared by using Exiqon's LNA TM technology.
Statistical analysis
Statistical analysis was performed by unpaired t test and one-way/two-way ANOVA or nonparametric t-test (Welch test) using Prism software (GraphPad Software, Inc.; San Diego, CA), as appropriate. All data were expressed as means±SEM. The level of p<0.05 was considered significant. The individual p-values are indicated in the figure legends.
Results
Muscle phenotype of Compact mice
Body-and muscle weight
We compared 2.5-month-old Mstn mutant Cmpt mice with wild-type BALB/c mice in terms of body and muscle weight. Cmpt male mice were significantly larger than BALB/c regarding their body weight. Absolute weights of the different hindlimb muscles, such as Quadr, Gastro, TA, EDL 6 and SOL muscles, were significantly larger in Cmpt mice. Similarly, muscle weights normalized to body weights were significantly increased in Cmpt animals, with the exception of the oxidative SOL muscle. These results indicated a disproportionate increase in muscle masses in Cmpt mice. To assure that the 2.5-month-old Cmpt mice had already finished the intense growing phase, we analyzed older mice as well. Body weight was similar in young (2.5-month-old) and adult (4-and 7-month-old) animals, while 12-23-month-old mice had slightly higher weight measurements.
However, no significant difference was found in muscle weights amongst any of the age groups, indicating that the 2.5-month-old animals have already reached muscle size typical of adult mice.
Muscle fiber number and fiber cross sectional area
To define whether the hypermuscularity of Cmpt mice is caused by hyperplasia or hypertrophy, we analyzed muscle fibers on HE-or MHC-immunostained serial cross-sections of different muscle types. Fiber number was significantly higher in all examined muscles of the 2.5-month-old Cmpt mice than that observed in wild-type mice. TA muscle revealed the most significant hyperplasia as compared with EDL and SOL muscles. However, fiber size did not differ in TA muscles between Cmpt and BALB/c mice. EDL and SOL muscles of Cmpt mice, on the other hand,
showed clear evidence of hypertrophy as well. To control fiber parameter alterations in Cmpt mice along with aging, we analyzed TA muscles of 7-month-old Cmpt mice and found no differences compared with 2.5-month-old mice.
In summary, based on our results, hypermuscularity of Cmpt mice is characterized by fiber hyperplasia in TA muscle and by a combination of hyperplasia and different grades of hypertrophy in EDL and SOL muscles.
MHC composition and fiber size distribution
To analyze the possible effects of the Cmpt mutation on MHC composition, serial cryosections of TA, EDL and SOL muscles were immunostained using sets of monoclonal antibodies in order to differentiate type I, IIA, IIX and IIB fibers, respectively. In line with the literature, only MHCII isoforms were detected in TA and EDL muscles of both mouse lines, whereas no MHCIIB fibers were found in SOL muscle.
We noted that the fast-type TA muscles of Cmpt mice contained significantly more glycolytic IIB fibers while a decreased number of IIX and IIA fibers as compared with that in wild-type mice.
Similar to TA muscles, the number of glycolytic IIB fibers was increased in the fast-type EDL muscles of Cmpt mice, while the number of IIX and IIA fibers was significantly lower as compared with that of wild-type mice. In contrast, the oxidative SOL muscles in Cmpt mice contained more slow-type I fibers and less fast-type IIA fibers than those in wild-type mice, while the number of IIX 7 fibers was very low and not different in the two mouse lines. Together, our findings clearly demonstrate a substantial shift toward a more glycolytic phenotype in the fast-type TA and EDL muscles but not in the mixed-type oxidative SOL muscles of Cmpt mice.
We could not detect specific hypertrophy for any of the IIB, IIX or IIA fiber types in TA muscles. In EDL muscles, however, fiber hypertrophy was exclusively found in IIB fibers. In contrast to fast muscles, both I and IIA fibers showed evidence of hypertrophy in SOL of Cmpt mice.
mRNA levels of MHC isoforms
According to qRT-PCR analysis of TA muscles, MHCIIB mRNA levels were significantly increased, while MHCIIX and MHCIIA transcript levels both decreased in Cmpt mice. The slow MHCI isoform was almost undetectable. These results are in line with those obtained by immunohistochemical analysis, suggesting that the fiber-type shift in the TA muscle is regulated at the level of MHC transcription.
Myostatin and IGF-I signaling in the human heart
Study patients
Both female and male patients were included in all groups. The age of ICM patients differed as expected significantly from both CONT and DCM, since ICM patients are usually diagnosed with end-stage heart failure later than DCM patients. Extra care was taken to exclude diabetic (insulintreated) patients from the study to avoid possible modification of the IGF-I signaling by insulin treatment. All patients were managed with angiotensin-converting enzyme (ACE)-inhibitors, betablockers and diuretics, however, aspirin and statins were only used in case of ICM patients. CONT subjects received iv. treatment composed of very low catecholamine infusion whereas adequate fluid balance was maintained with intravenous fluids including colloids (e.g. Voluven -hydroxyethyl starch) and Desmopressin.
Myostatin and IGF-I signaling in healthy human control hearts
So far, no comprehensive study has been carried out to reveal gene expression of the growth regulators Mstn and IGF-I and their receptors in different regions of healthy human hearts. In the present work we detected no significant difference in Mstn and ActRIIB transcript levels nor in Mstn signaling index between septum (S), left ventricle (LV) and right ventricle (RV), however, Mstn levels showed decreasing tendency in the RV. In contrast, both IGF-I mRNAs and IGF-I signaling index followed an increasing tendency in RV accompanied with a significantly higher IGF-IR levels compared to those of LV.
As a consequence, the ratio of Mstn/IGF-I gene expression as well as those of ActRIIB/IGF-I receptors and finally, the ratio of Mstn to IGF-I signaling all showed significantly higher values in 8 LV/S as compared to RV. These data clearly demonstrate that Mstn signaling dominates over IGF-I in the LV more than in RV of healthy human hearts.
Myostatin and IGF-I signaling in DCM patients compared to healthy controls
In DCM patients we measured massive upregulation of Mstn mRNA associated with an increased Mstn signaling index in all heart regions compared to CONT, although ActRIIB levels remained relatively unchanged. Similar to healthy hearts, we found a significant upregulation of IGF-I transcripts as well as of IGF-I signaling index in RV of the failing hearts when compared to those of S, although IGF-IR expression did not show significant difference in either region nor in comparison to CONT hearts. Thus, the ratio of Mstn/IGF-I mRNA levels and the Mstn/IGF-I signaling index proved to be significantly higher in the left versus right side of the DCM hearts and showed much higher levels than those of the CONT regions. Since the ratio of the ActRIIB/IGF-I receptors did not change significantly we can conclude that Mstn was upregulated in all regions of failing hearts in DCM patients as compared to CONT. However, given the higher IGF-I levels in RV, left and right side of failing heart differed significantly from each other in regard to the ratio of Mstn/IGF-I signaling similar to those of healthy ones.
Myostatin and IGF-I signaling in ICM patients compared to healthy controls
In contrast to DCM patients, we could not detect any difference in either Mstn or ActRIIB transcript levels or in Mstn signaling index in any heart region of ICM patients compared to those of CONT. Similarly, IGF-I and IGF-IR levels as well as IGF-I signaling index did not differ in ICM heart regions; however, in comparison to CONT, IGF-I showed a decreasing tendency of expression in the RV, while increased expression of IGF-IR in the LV was present. Consequently, both ratios of Mstn/IGF-I and ActRIIB/IGF-IR were similar in all analyzed regions of ICM hearts. However, significantly higher Mstn/IGF-I ratios were revealed in RV due to decreased IGF-I levels as well as significantly lower ActRIIB/IGF-IR ratios in LV when compared to CONT hearts (due to increased IGF-IR levels). In summary, ICM hearts did not show significantly altered modulation of Mstn signaling in either heart region, whereas IGF-I signaling, in contrast to the healthy situation, seemed to be moderately induced in the LV, while inhibited in the RV.
Differences in Myostatin/IGF-I signaling between DCM and ICM patients
Based on our results, all regions of DCM hearts showed significantly higher Mstn levels as well as elevated Mstn signaling index than those of ICM hearts. Moreover, ActRIIB also revealed increased levels in LV of DCM vs. ICM patients. Nevertheless, we found no significant difference in IGF-I signaling on the left side of failing hearts, although significantly less IGF-I transcripts were evident on the right side of ICM hearts in comparison with that of DCM ones. As a consequence, all 9 parameters describing the ratio of Mstn to IGF-I signaling showed significantly increased values in the LV of DCM versus ICM hearts. Although in the RV we have revealed similar signaling ratio in both types of failing hearts the reason for that was an upregulation of Mstn signaling in DCM patients while a downregulation of IGF-I signaling in ICM heart samples.
miR-208 in relation to myostatin expression in DCM and ICM patients compared to healthy controls
In parallel with the massive upregulation of Mstn mRNA in the LV of DCM patients we measured a mild upregulation of miR-208b (1.505 fold change) compared to CONT. A similar but less pronounced upregulation was seen in ICM hearts (1.405 fold change) when compared to CONT, however, no significant difference was detected between DCM and ICM patients.
Discussion
Mstn belongs to the TGF-β family and is a negative regulator of skeletal muscle growth.
However, it plays also a crucial role in governing heart growth, metabolism and contraction. Our aim was to describe different aspects of Mstn signaling in skeletal muscle and heart tissue. characteristics of BALB/c mice are similar to those of C57BL/6, another wild-type mice used as a genetic background for Mstn KO mice, suggesting that these lines might be comparable to some extent. In the present study we show, in accordance with others that body-and muscle weights of male Cmpt mice are higher than those of wild type BALB/c mice. Body mass is even higher in Cmpt mice (47,7g) than in male Mstn KO of the same age (38-41g), but represent a similar grade of muscularity. One exception was the SOL muscle, which seemed to be different in this regard, as its relative muscle-to body weight did not increase in Cmpt compared with the wild type mice. Indeed, it has previously been reported that the oxidative SOL muscle contained less Mstn transcript than the glycolytic EDL and, that the lack of Mstn had stronger effect on glycolytic muscles than on oxidative ones. Therefore, we analyzed three different hindlimb muscles: the fast-glycolytic TA and EDL as well as the oxidative SOL muscles in Cmpt mice. Based on extensive morphometrical analysis TA muscles were exclusively characterized by muscle fiber hyperplasia, with no obvious hypertrophy.
This observation may somewhat be surprising, as previous reports described both hyperplasia and hypertrophy in different Mstn KO animals. However, even in the original Mstn KO mouse study, the ratio of hyperplasia to hypertrophy varied in different muscles, e.g. the TA muscles of Mstn KO mice were dominated by hyperplasia, while only 14% fiber hypertrophy was documented. In contrast to TA, EDL muscles of Cmpt mice were characterized by a combination of hyperplasia (50%) and hypertrophy (20%), whereas EDL in the Mstn KO mice showed only a moderate hyperplasia and a stronger hypertrophy. We found that the moderate fiber hypertrophy in Cmpt EDL confined to the most glycolytic IIB fibers and was not present in IIX or IIA fibers. This is again in accordance with the previous reports on a stronger effect of Mstn on glycolytic muscles. We believe that the long separation of the 'Berlin' and Hungarian Cmpt lines, gender differences, the use of different controls as well as our detailed sample analysis may account for these differencies.
In the oxidative SOL muscle of Cmpt mice, low-grade hyperplasia (15%) and mainly hypertrophy (27%) accounted for the moderately higher muscle mass. Moreover, both the oxidative I and IIA fibers showed hypertrophy compared with the wild-type control. The changes in SOL are different from those of fast TA and EDL muscles in Cmpt line. Intriguingly, controversial results have been published regarding SOL in Mstn KO mice, where either 32% hyperplasia, or 20% fiber hypertrophy has been described. It is not known so far, how cellularity in different muscle types is regulated upon Mstn defect. However, prenatal hyperplasia seems to be the major effect of developmental Mstn deficiency in most muscles of mice and cattle. Based on the different ratio of hyperplasia to hypertrophy in various Mstn deficient muscles, Mstn might have a strong, but muscletype dependent effect on proliferation of muscle precursor cells. Consequently, postnatal fiber hypertrophy might be restricted to different grade. Rehfeldt and co-workers (2005) introgressed the Mstn mutant Cmpt allele into a special high growth mouse line (DUHi) and detected exclusively hyperplasia, similar to our results, in the predominantly fast rectus femoris and longissimus dorsi muscles. These data suggest that, at least in fast muscles, hyperplasia is even more pronounced in However, the oxidative SOL muscle has not shown any glycolytic shift in Cmpt mice (53% slow-oxidative type I fibers, 44% fast-oxidative IIA fibers) as compared with BALB/c line (38% type I fibers, 60% type IIA fibers). In contrast, these fibers were even more oxidative than the controls contradicting previous reports on Mstn KO mice. To conclude, different mechanisms of Mstn deficiency -with or without the influence of modifier genes-may induce differential and muscle-specific effects.
In summary, Cmpt mouse, inspite of its complex genetic background, shows similarities (at least in fast muscles) to Mstn KO mice in terms of muscle cellularity and glycolytic muscle phenotype, suggesting that the lack of Mstn is responsible for these morphological/functional changes. However, based on the more pronounced hyperplasia in Cmpt fast muscles as well as the different cellularity and oxidative phenotype of Cmpt SOL, additional studies are needed to elucidate the molecular mechanisms of Mstn inactivity and the possible role of modifier genes in Cmpt mice.
Myostatin and IGF-I signaling in the human heart
Mstn and IGF-I both have been shown to play a crucial role in the pathomechanism of human heart failure with upregulated Mstn protein in the failing myocardium. However, the exact mechanism and their possible interplay in the course of heart failure have not been clarified yet.
In the present comprehensive qRT-PCR study we have found that Mstn dominated over IGF-I signaling much more in the LV than in the RV of healthy human hearts, and that DCM hearts upregulated Mstn expression in contrast to ICM hearts. This is the first demonstration that Mstn/IGF-I signaling differs in LV and RV in healthy hearts and shows significant alterations in end-stage heart failure due to DCM and ICM.
Several studies exist in the literature, indicating the presence and/or de-regulation of both
Mstn and IGF-I under different conditions in the heart, however, the majority of data were collected from whole hearts or separately, from the LV. Regarding Mstn expression in healthy hearts, only one study has been published so far on higher transcript levels of Mstn in LV as compared to RV in young piglet hearts. In line with these data we have demonstrated here an obvious reciprocal regulation of Mstn and IGF-I in LV compared to RV characterized by elevated ratios of both Mstn/IGF-I and ActRIIB/IGF-IR transcripts in healthy human LV. Septum (S) samples, as being part of LV from the functional point of view, revealed similar values to those of LV in most cases. We assume that cardiomyocyte growth in LV/S should be balanced more tightly by growth inhibitors (i.e. Mstn) than that of RV since LV is exposed to higher-pressure overload, while RV to a relatively higher-volume overload. In addition to Mstn and IGF-I, several other factors have been reported to be enriched in either LV or RV; their asymmetric expression might reflect a molecular predisposition of myocardium to LV-concentric or RV-eccentric remodeling during postnatal development.
Similarly, higher expression levels in LV versus RV have been demonstrated for cytochrome c oxidases and PGC1α, both of which are known to contribute to maintain mitochondrial function and oxidative metabolism. Recently, it has been shown that Mstn plays an important role in the regulation of oxidative metabolism of the myocardium. Therefore our results support the idea that the elevated ratio of Mstn/IGF-I signaling is an important regulatory mechanism under physiological conditions maintaining higher workload and oxidative metabolism in the LV. These results are also in accordance with the glycolytic shift in skeletal muscles upon Mstn defect and suggest that Mstn exert similar metabolic effects in both skeletal muscle and cardiac tissues, at least in the LV.
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In human failing hearts (in whole hearts or LV), Mstn protein activation was reported to be accelerated in both DCM and ICM patients. In parallel with this observation several groups found increased serum levels of Mstn protein in patients suffering from heart failure, although no correlation was demonstrated with the severity or type of cardiac disease. One should also consider that elevated serum Mstn levels in cardiomyopathic patients might be a combined effect of increased secretion from both cardiac and skeletal muscles. Nevertheless, exercise training lead to a reduction of Mstn levels only in skeletal muscles but not in serum of patients with chronic heart failure.
Intriguingly, it has not been clarified, whether protein activation in failing heart is regulated either at the level of gene expression or posttranscriptionally. Here we show that DCM hearts are indeed characterized by upregulated Mstn transcripts in both LV/S and RV supporting the previous reports on protein activation in LV. However, we could not detect any significant elevation of Mstn transcript levels in ICM patients. We also tested the miRNA-dependent posttranscriptional regulation of Mstn. miR-208 have been reported to be a negative regulator of Mstn expression, and to be upregulated in various forms of cardiomyopathy and myocardial ischemia. In line with these, we detected a mild upregulation of miR-208b in the LV of DCM patients characterized by massive increase of Mstn transcripts that might suggest an adaptive counter-regulatory mechanism finetuning the expression of Mstn during heart failure. Since we have found no difference in miR-208b expression between DCM and ICM hearts, it is likely that increased Mstn mRNA in DCM is mainly regulated at the level of transcription. Although alterations in Mstn gene expression are followed by similar changes at the protein level in most cases, the intra-or extracellular proMstn-pool might be posttranslationally activated by the cleavage of the propeptide. Thus, ICM patients might have a Mstn activation at the protein level, however, not at the level of transcription, whereas DCM hearts react with significant upregulation of Mstn transcripts. Similar to the results of George et al. (2010) we detected lower level of ActRIIB in ICM than in DCM patients, but this occured only in the LV.
On the other hand, IGF-I expression was shown to be dynamically regulated in the course of heart failure as an important compensatory mechanism; however, conflicting data exist in the literature with both down-and upregulated IGF-I levels in end-stage heart failure. We could confirm significant decrease of IGF-I signaling in the RV of ICM patients but not in LV or DCM patients.
Moreover, DCM patients still maintained the physiological difference in Mstn/IGF-I signaling ratios in LV versus RV, whereas no asymmetric gene expression pattern was detected in ICM patients. The mechanisms leading to different regulation of growth factor signaling in DCM and ICM patients remain to be clarified, however, it might relate to the different pathomechanism of heart failure and/or alternative regulation of compensatory mechanisms. Indeed, Mstn upregulation detected in DCM hearts might be part of adaptation reactions since Biesemann et al (2014) have recently
